European Commission Approves Faslodex-Ibrance Combo for Advanced Breast Cancer

European Commission Approves Faslodex-Ibrance Combo for Advanced Breast Cancer
The European Commission (EC) has extended the approval of AstraZeneca's breast cancer therapy Faslodex (fulvestrant) to be used in combination with Ibrance (palbociclib) for advanced breast cancers. The combination can now be used to treat women with hormone receptor-positive (HR+), HER2-negative, locally advanced or metastatic breast cancer who have received prior hormone therapy. “For many years fulvestrant has been used as an effective monotherapy treatment for women with hormone receptor positive breast cancer," David Fredrickson, executive vice president, head of the Oncology Business Unit at AstraZeneca, said in a press release. "The first EU approval of fulvestrant for use in combination with a CDK4/6 inhibitor reinforces the value of fulvestrant as an endocrine agent of choice for advanced breast cancer patients, building on the EU first-line monotherapy approval earlier this year with FALCON.” Faslodex is a hormonal treatment approach that helps to slow tumor growth by targeting the estrogen receptor — one of the main drivers of disease progression. Pfizer’s Ibrance is an inhibitor of the cyclin-dependent kinases (CDK) 4 and 6, molecules that regulate cell division and proliferation. CDK4/6 inhibitors prevent cancer cells from multiplying excessively. Faslodex is already licensed in the U.S. for use with t
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.